Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model
Abstract Background Cognitive decline in Alzheimer’s disease (AD) is associated with hyperphosphorylated tau (pTau) propagation between neurons along synaptically connected networks, in part via extracellular vesicles (EVs). EV biogenesis is triggered by ceramide enrichment at the plasma membrane fr...
Main Authors: | Carolyn Tallon, Benjamin J. Bell, Medhinee M. Malvankar, Pragney Deme, Carlos Nogueras-Ortiz, Erden Eren, Ajit G. Thomas, Kristen R. Hollinger, Arindom Pal, Maja Mustapic, Meixiang Huang, Kaleem Coleman, Tawnjerae R. Joe, Rana Rais, Norman J. Haughey, Dimitrios Kapogiannis, Barbara S. Slusher |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-12-01
|
Series: | Translational Neurodegeneration |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40035-023-00383-9 |
Similar Items
-
Dendrimer-Conjugated nSMase2 Inhibitor Reduces Tau Propagation in Mice
by: Carolyn Tallon, et al.
Published: (2022-09-01) -
Neuronal deletion of nSMase2 reduces the production of Aβ and directly protects neurons
by: Sehmus Tohumeken, et al.
Published: (2023-02-01) -
Microglial-Targeted nSMase2 Inhibitor Fails to Reduce Tau Propagation in PS19 Mice
by: Meixiang Huang, et al.
Published: (2023-09-01) -
Ceramide Metabolism and Parkinson’s Disease—Therapeutic Targets
by: Antía Custodia, et al.
Published: (2021-06-01) -
Astrocytic ceramide as possible indicator of neuroinflammation
by: Nienke M. de Wit, et al.
Published: (2019-02-01)